



TECHNOPHAGE and PHAXIAM Therapeutics Enter Strategic Collaboration on Individualized Phages Therapies (IPT) Against Bacteria Responsible For ~ 70%⁽¹⁾ of the Most Common Severe Resistant Infections

- **Conjunct portfolio of 25 GMP phages targeting five critical pathogens (*Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Klebsiella pneumoniae*, and *Acinetobacter baumannii*) set for completion by the end of 2025, with plans to expand to 35-40 GMP phages and include two additional pathogens by the end of 2026.**
- **Opportunity to provide physicians with access to a comprehensive GMP phage portfolio and a diagnostic solution enabling the implementation of *Individualized Phages Therapies (IPT)*.**
- **Collaboration on the GMP phages manufacturing and *in vitro* diagnostic (IVD) capabilities development.**
- **Concurrently, both parties continue to independently develop their traditional clinical *Phages Therapy Medicinal Product (PTMP)* pathway.**

Lisbon (Portugal) / Lyon (France), January 30, 2025 – 06:00 pm CET – TECHNOPHAGE, SA (“TECHNOPHAGE”), a Portuguese company specializing in GMP phage development and **PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135)**, a biopharmaceutical company (“PHAXIAM”) developing innovative treatments for severe and resistant bacterial infections, announce today its intent to establish a strategic collaboration. This strategic partnership aims to provide physicians with access to a comprehensive GMP phage portfolio, enabling the implementation of IPT through shared capabilities.

This collaboration seeks to deliver a faster and more effective response to the growing challenge of severe resistant infections. By combining PHAXIAM’s GMP phages portfolio and advanced diagnostic capabilities, including its phagogram-based approach, with TECHNOPHAGE’s GMP phages portfolio and GMP manufacturing expertise, the partnership aims to drive innovation and accelerate access to IPT.

Expanding the GMP Phage Portfolio to Advance Individualized Phages Therapies (IPT)

The combined GMP phage portfolios will significantly enhance the number and diversity of GMP phages available for IPT. The partnership aims to achieve a collection of 25 GMP phages by the end of 2025 and 35-40 GMP phages by the end of 2026. This expanded portfolio will target at least 7 of the most critical pathogens: *S. aureus*, *P. aeruginosa*, *E. coli*, *K. pneumoniae*, *A. baumannii*, in addition to two other key pathogens targets. Together, these seven pathogens account for approximately 70%¹ of the most prevalent severe resistant infections.

Shared Manufacturing and Phagogram capabilities

TECHNOPHAGE and PHAXIAM will collaborate on GMP phage manufacture and supply through the following arrangements:

¹ Antimicrobial Resistance Collaborators, Lancet 2022; 399: 629–55.



- TECHNOPHAGE will produce and supply PHAXIAM with commercial batches of TECHNOPHAGE's GMP phages.
- PHAXIAM will produce and supply TECHNOPHAGE with commercial batches of PHAXIAM's GMP phages.

The phagogram platform - a critical *in vitro* testing tool for evaluating GMP phages against patient's bacterial strains - forms a cornerstone of this collaboration. PHAXIAM will develop and expand its phagogram capabilities by integrating new GMP phages provided by TECHNOPHAGE. These enhanced capabilities will then be transferred to TECHNOPHAGE's territory under undisclosed terms.

Individualized Phages Therapies (IPT) to Drive Revenues Growth in Major European Markets

Each party will manage the commercialization of the joint GMP phage portfolio within designated territories to be defined, leveraging on their respective strengths. The objective is to capitalize on the respective assets of both companies, considering (1) the level of interactions with regulatory authorities, (2) the potential commercial reach due to (a) the clinical deployment in any country through ongoing clinical trials, (b) the opening of clinical sites, and (c) distance from patients. The optimal commercial organization and the respective responsibilities of both companies will be defined according to the principles outlined earlier.

Both parties will pursue their respective clinical pathways for their own Phage Therapy Medicinal Products (PTMP)

TECHNOPHAGE will pursue the completion of REVERSE 2 (Phase 2b) and initiate REVERSE 3 (Phase 3), focusing on confirming the efficacy and safety of the Fast Track Designated TP-102 bacteriophage cocktail for the treatment of infected Diabetic Foot Ulcers in 2025; additionally, the company will launch the Phase 1/2a clinical trial of TP-122A (RECOVER) to evaluate the safety and tolerability of this phage cocktail in the context of Ventilator-Associated Pneumonia (VAP).

PHAXIAM will conduct GLORIA Phase II study, the 1st global, multicenter, randomized, placebo-controlled proof-of-concept phage therapy study in Prosthetic Joint Infection (PJI), conducted in Europe and the United States.

PTMP and IPT market channels form together a self-reinforcing virtuous cycle for Phages Therapy:

- Commercial success in IPT will help finance PTMP programs and facilitate rapid uptake of future approved medicinal products,
- Clinical success in PTMP will help broaden clinical and market acceptance of IPT in clinical indications not yet addressable by PTMP.

Miguel Garcia, Chief Executive Officer of TECHNOPHAGE, stated: *"Technophage has long been dedicated to advancing phage therapy as a revolutionary approach to treating bacterial infections. Our partnership with PHAXIAM enables us to combine our strengths and expedite patient access to high-quality individualized phage-based treatments. This collaboration represents a vital step in establishing phage therapy as a key therapeutic option, while aligning with our long-term goal of introducing innovative phage-based products to the biopharmaceutical market."*

Thibaut du Fayet, Chief Executive Officer of PHAXIAM, added: *"This strategic collaboration represents a major advancement in the fight against severe resistant infections. By combining our respective areas of expertise and capabilities, we are presenting a compelling value proposition designed to deliver more effective, individualized therapies to patients. This partnership further*



supports our IPT model while accelerating our strategic development and strengthening our leadership position in the rapidly growing phages therapy market."

Contacts

Technophage S.A.

Miguel Garcia

CEO

Phone : +(351) 215 943 993

E-mail: info@technophage.pt

About TECHNOPHAGE

TECHNOPHAGE's mission is to develop innovative biologics to address the therapeutic needs of unmet medical conditions in infection, neurosciences, and ophthalmology. The company believes that its role in bringing safe and effective therapeutics to the market will significantly contribute to helping patients across the globe who are unable to find solutions in existing medicines.

The company's vision is to become a worldwide reference by providing unique and innovative solutions for unmet medical needs, leveraging its proximity to local healthcare systems. TECHNOPHAGE believes that its purpose of discovering alternative therapeutic solutions for unmet needs through the development of unique and innovative biologics can only be achieved by working every day to establish itself as a global partner. As the world faces increasing challenges in healthcare, the company's commitment is to be part of the solution.

For more information, please visit: www.technophage.pt

About PHAXIAM Therapeutics

PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: *Staphylococcus aureus*, *Escherichia coli* and *Pseudomonas aeruginosa*.

PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

For more information, please visit www.phaxiam.com